Dr. Reddy'S Brasil

Dr. Reddy'S Brasil company information, Employees & Contact Information

A Dr. Reddy’s é uma empresa global, com qualidade mundialmente reconhecida. Hoje, estamos presentes em mais de 30 países, contamos com 10 centros de pesquisa e desenvolvimento, possuímos 25 fábricas espalhadas pelos Estados Unidos, pela Europa e pela Índia e atualmente, contamos com mais de 20.000 colaboradores em todo o mundo, dedicados a fazerem diferença na vida das pessoas. No Brasil, atuamos desde 2004 e produzimos medicamentos e produtos para a saúde nas seguintes especialidades: oncologia, hematologia, hospitalar e radioterapia. Além disso, em 2015, demos início a uma nova estratégia, focada no lançamento de produtos de alta complexidade e com alto padrão de qualidade. Como uma das maiores empresas farmacêuticas de genéricos no mundo, temos claro nosso propósito: garantir, facilitar e acelerar o acesso a remédios de qualidade para todos, afinal, Good Health Can’t Wait. Siga a Dr. Reddy's Brasil nas redes sociais: Facebook: web.facebook.com/drreddysbrasil Instagram: instagram.com/drreddys.brasil/ Confira nossas Diretrizes de Comunidade (em Inglês): https://www.drreddys.com/cms/cms/sites/default/files/2024-08/Community_Guidelines_-_LinkedIn.pdf

Company Details

Employees
40
Founded
-
Address
Avenida Guido Caloi 1985, São Paulo,sp 05802-140,brazil
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
Analyst jobs.
HQ
São Paulo, SP
Looking for a particular Dr. Reddy'S Brasil employee's phone or email?

Dr. Reddy's Brasil Questions

News

Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs - Clinton Health Access Initiative

Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs Clinton Health Access Initiative

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia - PR Newswire

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia PR Newswire

Dr. Reddy’s Q3 & 9MFY25 Financial Results - Business Wire

Dr. Reddy’s Q3 & 9MFY25 Financial Results Business Wire

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag - Business Wire

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag Business Wire

Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business - NTB Kommunikasjon

Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business NTB Kommunikasjon

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe - Business Wire

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe Business Wire

EX-99.1 - SEC.gov

EX-99.1 SEC.gov

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market - Business Wire

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market Business Wire

Dr. Reddy’s Q2 & H1FY25 Financial Results - Business Wire

Dr. Reddy’s Q2 & H1FY25 Financial Results Business Wire

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma - Business Wire

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma Business Wire

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America - Business Wire

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America Business Wire

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year - Business Wire

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year Business Wire

Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S. - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S. Business Wire

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio - Business Wire

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio Business Wire

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK - Business Wire

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK Business Wire

Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar - Business Wire

Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar Business Wire

Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma - Business Wire

Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma Business Wire

Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market - PR Newswire

Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market PR Newswire

Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia - ANTARA News

Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia ANTARA News

This contact info of Dr. Reddy’s regarding 2DG drug procurement is incorrect - FACTLY

This contact info of Dr. Reddy’s regarding 2DG drug procurement is incorrect FACTLY

The world’s pill factory | D+C - Development + Cooperation - Dandc.eu

The world’s pill factory | D+C - Development + Cooperation Dandc.eu

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant